Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 17/20 | 0.49 |
| ▸ | LTB4R2 | Q9NPC1 | 14/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6803419 | 0.86 | LTB4R (0.60) | LTB4RLTB4R2 | |
| SCHEMBL6807550 | 0.83 | LTB4R (0.51) | LTB4RLTB4R2 | |
| SCHEMBL7633423 | 0.77 | LTB4R (0.48) | LTB4RLTB4R2HSP90AA1MAPTHTT | |
| SCHEMBL6807256 | 0.76 | LTB4R (0.64) | LTB4RLTB4R2 | |
| SCHEMBL7633418 | 0.76 | LTB4R (0.51) | LTB4RLTB4R2 | |
| SCHEMBL8949707 | 0.74 | LTB4R (0.79) | LTB4RLTB4R2 | |
| SCHEMBL6892457 | 0.73 | LTB4R (0.83) | LTB4RLTB4R2 | |
| SCHEMBL6806846 | 0.73 | LTB4R (0.67) | LTB4RLTB4R2 | |
| SCHEMBL6806853 | 0.73 | LTB4R (0.62) | LTB4RLTB4R2 | |
| SCHEMBL6806717 | 0.73 | LTB4R (0.54) | LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1231938-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001034137-A2 | ONCOLYTIC COMBINATIONS FOR THE TREATMENT OF CANCER | ELI LILLY AND COMPANY (US) | 2001-05-17 | — | — | WO | disclosed |